BACKGROUND: The cause of chronic fatigue syndrome (CFS) is unknown but is thought to be associated with immune abnormalities or infection. Because cancer can arise from similar conditions, associations between CFS and cancer were examined in a population-based case-control study among the US elderly. METHODS: Using linked Surveillance, Epidemiology, and End Results (SEER)-Medicare registry data, approximately 1.2 million cancer cases and 100,000 controls (age range, 66-99 years; 1992-2005) were evaluated. CFS was identified in the period more than 1 year prior to selection, using linked Medicare claims. Unconditional logistic regression was used to estimate the odds ratios (ORs) comparing the CFS prevalence in cases and controls, adjusting for age, sex, and selection year. All statistical tests were 2-sided. RESULTS: CFS was present in 0.5% of cancer cases overall and 0.5% of controls. CFS was associated with an increased risk of non-Hodgkin lymphoma (NHL) (OR = 1.29, 95% confidence interval [CI] = 1.16-1.43, P = 1.7 × 10(-6) ). Among NHL subtypes, CFS was associated with diffuse large B cell lymphoma (OR = 1.34, 95% CI = 1.12-1.61), marginal zone lymphoma (OR = 1.88, 95% CI = 1.38-2.57), and B cell NHL not otherwise specified (OR = 1.51, 95% CI = 1.03-2.23). CFS associations with NHL overall and NHL subtypes remained elevated after excluding patients with medical conditions related to CFS or NHL, such as autoimmune conditions. CFS was also associated, although not after multiple comparison adjustment, with cancers of the pancreas (OR = 1.25, 95% CI = 1.07-1.47), kidney (OR = 1.27, 95% CI = 1.07-1.49), breast (OR = 0.85, 95% CI = 0.74-0.98), and oral cavity and pharynx (OR = 0.70, 95% CI = 0.49-1.00). CONCLUSIONS: Chronic immune activation or an infection associated with CFS may play a role in explaining the increased risk of NHL.
BACKGROUND: The cause of chronic fatigue syndrome (CFS) is unknown but is thought to be associated with immune abnormalities or infection. Because cancer can arise from similar conditions, associations between CFS and cancer were examined in a population-based case-control study among the US elderly. METHODS: Using linked Surveillance, Epidemiology, and End Results (SEER)-Medicare registry data, approximately 1.2 million cancer cases and 100,000 controls (age range, 66-99 years; 1992-2005) were evaluated. CFS was identified in the period more than 1 year prior to selection, using linked Medicare claims. Unconditional logistic regression was used to estimate the odds ratios (ORs) comparing the CFS prevalence in cases and controls, adjusting for age, sex, and selection year. All statistical tests were 2-sided. RESULTS: CFS was present in 0.5% of cancer cases overall and 0.5% of controls. CFS was associated with an increased risk of non-Hodgkin lymphoma (NHL) (OR = 1.29, 95% confidence interval [CI] = 1.16-1.43, P = 1.7 × 10(-6) ). Among NHL subtypes, CFS was associated with diffuse large B cell lymphoma (OR = 1.34, 95% CI = 1.12-1.61), marginal zone lymphoma (OR = 1.88, 95% CI = 1.38-2.57), and B cell NHL not otherwise specified (OR = 1.51, 95% CI = 1.03-2.23). CFS associations with NHL overall and NHL subtypes remained elevated after excluding patients with medical conditions related to CFS or NHL, such as autoimmune conditions. CFS was also associated, although not after multiple comparison adjustment, with cancers of the pancreas (OR = 1.25, 95% CI = 1.07-1.47), kidney (OR = 1.27, 95% CI = 1.07-1.49), breast (OR = 0.85, 95% CI = 0.74-0.98), and oral cavity and pharynx (OR = 0.70, 95% CI = 0.49-1.00). CONCLUSIONS: Chronic immune activation or an infection associated with CFS may play a role in explaining the increased risk of NHL.
Authors: P H Levine; D Peterson; F L McNamee; K O'Brien; G Gridley; M Hagerty; J Brady; T Fears; M Atherton; R Hoover Journal: Cancer Res Date: 1992-10-01 Impact factor: 12.701
Authors: M Caligiuri; C Murray; D Buchwald; H Levine; P Cheney; D Peterson; A L Komaroff; J Ritz Journal: J Immunol Date: 1987-11-15 Impact factor: 5.422
Authors: Konstance Knox; Donald Carrigan; Graham Simmons; Fernando Teque; Yanchen Zhou; John Hackett; Xiaoxing Qiu; Ka-Cheung Luk; Gerald Schochetman; Allyn Knox; Andreas M Kogelnik; Jay A Levy Journal: Science Date: 2011-05-31 Impact factor: 47.728
Authors: Michele Reyes; Rosane Nisenbaum; David C Hoaglin; Elizabeth R Unger; Carol Emmons; Bonnie Randall; John A Stewart; Susan Abbey; James F Jones; Nelson Gantz; Sarah Minden; William C Reeves Journal: Arch Intern Med Date: 2003-07-14
Authors: D Racciatti; M Dalessandro; L Delle Donne; K Falasca; P Zingariello; R Paganelli; E Pizzigallo; J Vecchiet Journal: Int J Immunopathol Pharmacol Date: 2004 May-Aug Impact factor: 3.219
Authors: D Michal Freedman; Jincao Wu; Honglei Chen; Eric A Engels; Lindsey R Enewold; Neal D Freedman; James J Goedert; Ralph W Kuncl; Mitchell H Gail; Ruth M Pfeiffer Journal: Int J Epidemiol Date: 2016-03-17 Impact factor: 7.196
Authors: Jose G Montoya; Tyson H Holmes; Jill N Anderson; Holden T Maecker; Yael Rosenberg-Hasson; Ian J Valencia; Lily Chu; Jarred W Younger; Cristina M Tato; Mark M Davis Journal: Proc Natl Acad Sci U S A Date: 2017-07-31 Impact factor: 11.205
Authors: Mady Hornig; José G Montoya; Nancy G Klimas; Susan Levine; Donna Felsenstein; Lucinda Bateman; Daniel L Peterson; C Gunnar Gottschalk; Andrew F Schultz; Xiaoyu Che; Meredith L Eddy; Anthony L Komaroff; W Ian Lipkin Journal: Sci Adv Date: 2015-02 Impact factor: 14.136
Authors: A Martin Lerner; Maria E Ariza; Marshall Williams; Leonard Jason; Safedin Beqaj; James T Fitzgerald; Stanley Lemeshow; Ronald Glaser Journal: PLoS One Date: 2012-11-14 Impact factor: 3.240